Albany, NY -- (SBWIRE) -- 01/20/2015 -- The independent clinical laboratory industry starts relatively late in China, featuring a limited overall size but high-speed development. In 2013 the independent clinical laboratory market size there was around RMB3.5 billion, up as much as 70% yr-on-yr, yet only accounting for 2%-3% of the total revenue of medical diagnosis.

There are about 110 independent clinical laboratories in today's China, but most of them are small sized. KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene as the strong performers thereof hold a combined market share of roughly 70%.

View Full Report
http://www.marketresearchreports.biz/analysis/226611

Because of a high requirement on the samples within a shorter time limit for place, the industry has a certain service radius. Therefore, a national layout is essential to business development and customer acquisition and chain-orientation the key development mode, for enterprises. KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene have by far 19, 15, 14 and 8 independent medical laboratories across the country.

KingMed Diagnostics as the largest independent clinical laboratory enterprise in China enjoys a market share of approximately 40%, receiving recognition from both College of American Pathologists (CAP) and ISO15189. In the first half of 2014 it posted revenue of RMB846 million, up 37% yr-on-yr. Equipped with detection platforms for tumor diseases, genetic diseases, blood diseases, etc., KingMed Diagnostics will give top priority to tumor, reproduction and microbiological testing in the future.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/226611

ADICON is the first independent medical laboratory in domestic trans-regional chain operation, with a market share as high as 15%-18%. In recent years, many of its subsidiaries have successively won ISO15189 and CAP certificates

As an industry leader in the business model of "service + agent", DIAN Diagnostics gets involved in independent clinical laboratory, judicial expertise, diagnostic products agency and other areas. Currently, the company boasts an 18% market share in the Chinese independent clinical laboratory industry, capable of carrying out more than 1,000 medical diagnostic services.

Explore All Latest Published Reports By Research In China
http://www.marketresearchreports.biz/publisher/67

Moreover, related enterprises abroad have also been well aware of the growth potential in China's independent clinical laboratory industry, and set foot in the Chinese market via cooperation with local companies.

In February 2012, Quest and KingMed Diagnostics entered into a strategic alliance and established the KingMed&Quest Diagnostics Alliance Laboratory. And the Tianbo Lab jointly set up bythe South Korea-based SK Group and Xi'an Tianlong Science & Technology Co.Ltd started business in July 2014.

Related Reports

China Pharmaceutical Excipients Industry Report, 2014-2017

View Full Report
http://www.marketresearchreports.biz/analysis/232334

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/232334

China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose rank as the top 10 pharmaceutical excipients in China.

China Recombinant Protein Drug Industry Report, 2014-2017

View Full Report
http://www.marketresearchreports.biz/analysis/232274

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/232274

The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

About MarketResearchReports.biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse Blog at http://marketpressrelease.wordpress.com/

Contact Us:
Office: State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: 518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz